<DOC>
	<DOCNO>NCT00014638</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth cancer cell . Letrozole may fight breast cancer reduce production estrogen . PURPOSE : Phase IV trial study effectiveness letrozole treat postmenopausal woman metastatic breast cancer previously treat tamoxifen .</brief_summary>
	<brief_title>Letrozole Treating Postmenopausal Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine time progression postmenopausal woman metastatic breast cancer treat letrozole ( Femara ) first-line therapy . II . Determine objective response rate , time treatment failure , survival rate , change symptom distress patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord time diagnosis metastatic disease . Patients receive oral letrozole ( Femara ) daily . Treatment continue absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 590 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic breast cancer Measurable evaluable disease Postmenopausal No spontaneous menses least 5 year ( include chemotherapyinduced amenorrhea ) Spontaneous menses within past 5 year allow amenorrheic least 12 month LH FSH postmenopausal normal range ( include chemotherapyinduced amenorrhea ) Bilateral oophorectomy Radiotherapy castration amenorrheic least 3 month Hormone receptor status : Estrogenreceptor ( ER ) and/or progesteronereceptor ( PR ) positive No ER PR negative unknown tumor PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : See Disease Characteristics Performance status : Karnofsky 50100 % WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Corrected serum calcium le 11.6 mg/dL Other : No known hypersensitivity constituent study drug No history noncompliance medical regimens No unreliability Not pregnant nursing Fertile patient must use effective contraception HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent anticancer immunotherapy biological response modifier Chemotherapy : See Disease Characteristics Prior adjuvant neoadjuvant chemotherapy adjuvant tamoxifen allow No concurrent anticancer chemotherapy Endocrine therapy : See Chemotherapy No concurrent anticancer endocrine therapy ( include steroid ) Radiotherapy : See Disease Characteristics No concurrent radiotherapy sole site disease Concurrent radiotherapy limit area ( e.g. , painful disease ) allow Surgery : See Disease Characteristics No prior adrenalectomy hypophysectomy Other : At least 30 day since prior systemic investigational drug At least 7 day since prior topical investigational drug No concurrent investigational drug Concurrent bisphosphonates ( e.g. , zoledronic acid ) bone metastasis allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>